Metronidazole Bailly-Creat (Metronidazole)

Metronidazole is taken up by susceptible microorganisms and reduced by their anaerobic electron‑transport proteins to form nitro radicals. These reactive species damage DNA and inhibit nucleic acid synthesis, ultimately causing cell death of the targeted bacteria or protozoa.

The dosage of Metronidazole Bailly-Creat is determined by the prescribing clinician based on the specific infection, patient age, weight, renal function, and other clinical factors. Patients should follow the exact regimen provided on the prescription label.

Safety in pregnancy and lactation has not been definitively established. The drug should only be used if the potential benefits justify any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metronidazole belongs to the nitroimidazole class and is uniquely effective against obligate anaerobes and certain protozoa. Compared with broad‑spectrum beta‑lactams, it offers targeted activity with a well‑characterised safety profile, making it a first‑line choice for many anaerobic infections when susceptibility is confirmed.

Metronidazole Bailly-Creat should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and heat sources to maintain its stability and potency.

The medication is administered orally, typically as tablets or capsules, and should be taken with or without food as directed by the prescriber. Swallow the dosage form whole with a full glass of water and complete the full course even if symptoms improve.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, liver toxicity, and blood dyscrasias. Patients should seek immediate medical attention if they experience neurological changes, rash, jaundice, or unusual bleeding.

Individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds should avoid this medication. Caution is also advised for patients with severe hepatic or renal impairment, and those who are pregnant or breastfeeding should only use it when clearly indicated by a healthcare professional.